Abstract: |
Prostatic tissue extracts from patients with benign prostatic hyperplasia (BPH) and prostatic carcinoma were fractionated using heparin‐Sepharose chromatography. The mitogenic activity of eluted fractions on quiescent subconfluent Swiss Albino 3T3 fibroblasts was tested employing a tritiated‐thymidine‐incorporation assay. Two peaks of activity were consistently noted—one in the void volume and a second fraction which eluted with 1.3–1.6 M NaCl and contained the majority of the mitogenic activity. Both non‐heparin‐ and heparin‐binding fractions increased tritiated thymidine incorporation into a mouse osteoblast cell line (MC3T3), while only the heparin‐binding fractions stimulated a human umbilical vein endothelial cell line (HUV). No increased uptake of thymidine was seen using a human prostatic carcinoma cell line (PC‐3). Sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) of lyophilized active fractions showed a persistent band at 17,500 daltons. The purified protein demonstrated angiogenic properties using the chick embryo chorioallantoic membrane (CAM) assay. Western blot analysis using antibodies specific to basic fibroblast growth factor (bFGF) or acidic FGF (aFGF) demonstrated that the former, but not the latter, bound to prostatic growth factor (PrGF), and inhibited its mitogenic activity as well. It appears that PrGF shares homology with basic fibroblast growth factors. Copyright © 1988 Wiley‐Liss, Inc., A Wiley Company |
Keywords: |
nonhuman; comparative study; mouse; animal; mice; cells, cultured; dose-response relationship, drug; angiogenesis; fibroblast growth factor 2; prostate; cell culture; heparin; fibroblast; fibroblasts; immunoassay; prostate hypertrophy; growth factor; drug binding; electrophoresis; prostate carcinoma; electrophoresis, polyacrylamide gel; chick embryo; mitogens; growth substances; chromatography; chorion; human; male; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; heparin‐binding; allantois
|
Notes: |
Article -- Export Date: 6 August 2020 -- Source: Scopus; Acknowledgements: The authors would like to thank Dr. Robert Ramsay, Dept. of Molecular Biology, MSKCC, for his helpful advice. We also thank Mr. Robert Huryk and Ms. Carol Mirenda, of the Urologic Oncology Research Laboratory, for their excellent technical assistance. |